Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing genome editing treatments intended to address serious diseases. Its in vivo pipeline includes NTLA-2001, which is in Phase 1 clinical testing for transthyretin amyloidosis, and NTLA-2002, which is being evaluated in a Phase 1/2 study for hereditary angioedema. The company also maintains collaboration and license agreements with AvenCell Therapeutics, Kyverna Therapeutics, ONK Therapeutics, and ReCode Therapeutics to advance programs in areas including allogeneic CAR-T therapies, autoimmune disease, engineered NK cell therapies, and genomic medicines for cystic fibrosis. Intellia Therapeutics was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NTLA
|
$13.74
|
19.2% Upside
|
Undervalued
|
$26.17
|
126.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-4.1x
|
2.6x
|
24.3x
|
1.526 B
|
1.007 B
|
5.0%
|
95.9%
|
0.6
|
—
|
92.2%
|
